Andrew M Haidle

发表

Augmenting Hit Identification by Virtual Screening Techniques in Small Molecule Drug Discovery

Xin Cindy Yan, John Sanders, Ying Duo Gao, 2020, J. Chem. Inf. Model..

Informing the Selection of Screening Hit Series with in Silico Absorption, Distribution, Metabolism, Excretion, and Toxicity Profiles.

Andreas Verras, Robert P Sheridan, J Christopher Culberson, 2017, Journal of medicinal chemistry.

Thiophene carboxamide inhibitors of JAK2 as potential treatments for myleoproliferative neoplasms.

Thomas Rush, Andrew M Haidle, Michael D Altman, 2014, Bioorganic & medicinal chemistry letters.

Building a Culture of Medicinal Chemistry Knowledge Sharing.

Andrew M Haidle, I. Raheem, Yeon-Hee Lim, 2022, Journal of medicinal chemistry.

A one-step, multi-component reaction for the synthesis of fully substituted 5-amino-4-carboxamidthiazoles

Andrew M Haidle, J. Rogers, M. Machacek, 2013 .

A practical, two-step synthesis of 1-alkyl-4-aminopyrazoles

Andrew M Haidle, Anna A. Zabierek, Kaleen M. Konrad, 2008 .

An enantioselective, modular, and general route to the cytochalasins: synthesis of L-696,474 and cytochalasin B.

Andrew M Haidle, A. Myers, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.

Andrew M Haidle, Matthew L. Maddess, J. Cumming, 2022, Journal of medicinal chemistry.

Efficacious Intermittent Dosing of a Novel JAK2 Inhibitor in Mouse Models of Polycythemia Vera

Shuxia Zhao, Joe Zhu, Lin Xu, 2012, PloS one.

An orally available non-nucleotide STING agonist with antitumor activity

Andrew M Haidle, J. Cumming, I. Kariv, 2020, Science.

Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells

Andrew M Haidle, Chunsheng Zhang, Yongxin Han, 2021, Oncoimmunology.

Carboxamide Spleen Tyrosine Kinase (Syk) Inhibitors: Leveraging Ground State Interactions To Accelerate Optimization.

Andrew M Haidle, Matthew L. Maddess, Youwei Yan, 2016, ACS medicinal chemistry letters.

Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.

Andrew M Haidle, H. Su, S. Munshi, 2017, Bioorganic & medicinal chemistry letters.

MARK inhibitors: Declaring a No-Go decision on a chemical series based on extensive DMPK experimentation.

Andrew M Haidle, M. Altman, A. Szewczak, 2017, Bioorganic & medicinal chemistry letters.

Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.

Andrew M Haidle, Matthew L. Maddess, H. Houshyar, 2015, Journal of medicinal chemistry.